Dermatology Program

About Guardian Therapeutics

Guardian Therapeutics is a private, pre-revenue biotech pioneering the development of aptamer drug conjugates (ApDCs) and other aptamer therapeutics. The company's platform enables rapid discovery of therapeutic aptamers with high affinity and stability, targeting a broad pipeline across hematology, gastroenterology, dermatology, and oncology. Led by co-founders CEO Jim Gilbert, MD, and CSO Shuhao Zhu, PhD, the company is advancing its platform and pipeline from its headquarters in Lowell, Massachusetts. Guardian's strategy positions it to capitalize on the potential advantages of aptamers over traditional antibody-based therapies.

About Animate Biosciences

Animate Biosciences is an early-stage biotech (founded 2021) pioneering an AI-powered platform for regenerative peptide therapeutics. The company targets pathological tissue remodeling, a process implicated in nearly half of global deaths, across multiple organ systems including pulmonary, dermatology, cardiac, and hepatic. By combining multi-omic data from regenerative organisms with generative AI, Animate aims to rapidly design and develop scalable therapeutics for conditions with limited treatment options. Its leadership team brings together expertise in regenerative biology, machine learning, and biotech entrepreneurship.

About Novaliq

Novaliq is a private, clinical-stage biotech pioneering a novel, water-free drug delivery platform (EyeSol®) for ophthalmology. Its technology is designed to enhance drug bioavailability, retention time, and tolerability on the ocular surface. The company has achieved its first commercial approvals in the US for dry eye disease (NOV03, CyclASol) and is advancing a pipeline targeting glaucoma, diabetic retinopathy, dermatology, and uveitis. With a seasoned management team and strategic partnerships, Novaliq is positioned to challenge the standard of care in topical ocular therapeutics.

Therapeutic Areas